Pulmonary arterial hypertension (PAH) is a progressive and chronic disease where the arteries that supply blood to the lungs get constricted and results in symptoms like fatigue, shortness of breath, and, heart palpitations.
In PAH the right side of the heart works too hard to pump blood due to hypertension and due to this, the right-side heart failure happens. It is significantly less regular than systematic blood pressure, which speaks to the power of blood traveling through veins all through the whole body.
New research published in the American Heart Association’s journal “Hypertension” finds that some bacterias are found in the gut that can guess and contribute to the development of pulmonary arterial hypertension (PAH).
The presence of a collection of bacteria in the gut is called microbiota and researchers predict PAH with more than eighty percent accuracy in those having microbiota profiles in the gut.
The lead study author and the professor in the departments of functional genomics and physiology at the University of Florida College of Medicine in Gainesville, Fla, Mohan Raizada explains that the present study shows that specific bacteria are present in the gut in people with PAH. It happens the first time that the presence of specific bacteria in the gut with PAH is identified. Also, this study opens the door for many new therapies centered on the digestive system.
The researchers had taken stool samples from some patients of PAH and some people who have never experience cardiopulmonary disease. The microbiota DNA was isolated and sequenced that were taken from stool samples. This test helped to know that a specific group of bacteria is responsible for PAH in PAH patients.
It is revealed the first time that a specific collection of bacteria is linked to pulmonary arterial hypertension (PAH). While in past researches gut microbiota profiles are linked with the number of heart diseases including hypertension.
The changes in Gut microbiota are dependent on the food a man eats, genetic makeup and environment and changes constantly. But Raizada finds that the bacteria linked with PAH do not change constantly and are unique bacteria. And researchers believe that these specific bacteria are constant.
The unique bacterial profile makes it possible to diagnose PAH earlier. Also, invasive heart catheterization could be replaced that is used to diagnose the disease. And many new treatment methods can be developed to alter the gut microbiome of PAH patients. Hence, it’s a hope for halting the progression of the disease.
Raizada tells that researchers don’t know the impact of viruses and gut bacteria on the lungs of PAH but some studies point that an increased rate in intestinal leakage among individuals with aspiratory hypertension may permit some intestinal bacteria to get into the circulatory system and course to the lungs where the inflammation and vascular changes are caused due to them.
But still, the question arises whether the particular microbiota linked with PAH is the cause of disease or not.